Search results for: "artificial intelligence"

Today’s guest post is by Reed Smith‘s Jamie Lanphear. She has long been interested in tech issues, and particularly in how they might intersect with product liability. This post examines product liability implications of using artificial intelligence (“AI”) for medical purposes. It’s a fascinating subject, and as always our guest posters deserve 100%…

We’ve become aware that some clients are using artificial intelligence (AI) to summarize or analyze things like complaints, briefs, internal documents, or even – horror of horrors! – law firm bills.  If the client performing these tasks is an in-house lawyer, such work might be protected by the attorney client privilege or work product doctrine…

Not quite three years ago, we co-authored a chapter in a Digital Health guide put out by International Comparative Legal Guides.  It bore the pithy title “Predicting Risk and Examining the Intersection of Traditional Principles of Product Liability Laws with Digital Health.”  We continue to tinker with the principles of product liability law…

Since it was published in 2011, the third edition of the Federal Judicial Center’s Reference Manual for Scientific Evidence has been the go-to guide for federal judges seeking to sort out scientific testimony, and a major source of non-precedential authority for both sides when arguing motions under Fed. R. Evid. 702.  2011, however, was fifteen…

This “just desserts” story caught our eyes earlier this year – a hot-shot expert witness, on artificial intelligence, no less, got caught with his own hand in the AI cookie jar.  As a result, his credibility was destroyed, and his testimony was excluded.  The litigation leading to Kohls v. Ellison, 2025 WL 66514 (D.

If you’re an in-house counsel working in the pharmaceutical, biotech, medical device, or digital health space (and still looking to complete CLE hours before year-end) we invite you to join Reed Smith’s annual Virtual Life Sciences CLE Week, taking place November 3–7, 2025.

This week-long event will feature a series of live webinars…

Drug & Device Resources

Bexis’ Book

FDA-regulated products now account for an estimated one-fifth of overall economic activity in the U.S. They have also been the focus of a litigation explosion. This timely guide covers all aspects of litigation involving drugs, medical devices, vaccines and other FDA-regulated prescription products.
Learn more about this book